Bryan Garnier - NEL (NEL.OL) NEL: CMD : attractive roadmap in terms of product development and cost reduction | BUY | NOK33(-1%)

Report

Bryan Garnier

Xavier Regnard

NEL: CMD : attractive roadmap in terms of product development and cost reduction | BUY | NOK33(-1%)

NEL - BUY | NOK33(-1%)
CMD : attractive roadmap in terms of product development and cost reduction

$1.5/kg by 2025 - achievable but under specific conditions
Increasing production capacity to cut costs by >40%
Further product development to improve the efficiency of the systems
Ready to acquire new technologies
Positive stance confirmed. Buy rating, TP NOK33

25/01/2021 5 EN

Underlying

NEL

See profile

Provider

Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

See profile

Analysts

Xavier Regnard

Other Reports on these Companies

Bryan Garnier

Energy transition & Sustainability Green hydrogen finally ready for take-off | HydrogenPro initiation of coverage Buy – Tprice NOK50/share

The green hydrogen market is moving from a proof-of-concept stage to commercial implementation, accompanied by strong growth in equipment sales. According to BloombergNEF (BNEF), electrolyser sales are projected to at least quadruple in 2022, from c.460 MW in 2021 to 1.8-2.5 GW in 2022, depending on the scenario HydrogenPro initiation of coverage Buy – Tprice NOK50/share Ceres Power Still one of our favourite stocks in the sector ITM Power Struggling to deliver on time McPhy Heading for new cuts in consensus estimates NEL Well positioned in the US market

September 30, 2022 September 30, 2022 1 EN

Bryan Garnier

NEL: Record order for 200 MW of alkaline electrolyser | SELL | NOK10

NEL - SELL | NOK10 Record order for 200 MW of alkaline electrolyser Nel’s largest purchase order to date Strong improvement in cost competitiveness Good news but probably no consensus upward adjustment as expectations were already ambitious

July 18, 2022 July 18, 2022 1 EN

Bryan Garnier

NEL: Top-line below expectations, challenged by supply chain disruptions | SELL | NOK10

NEL - SELL | NOK10 Top-line below expectations, challenged by supply chain disruptions Big miss on the top-line and wider than expected EBITDA loss What about FY’22 consensus expectations ? Sell rating confirmed

May 11, 2022 May 11, 2022 1 EN

Eutelsat: EUR1.35bn raise and step towards becoming a strategic French asset

Eutelsat has announced a EUR1.35bn equity raise, including a EUR716m reserved capital increase at EUR4/share and a EUR634m rights issue, underwritten by the French State, Bharti, CMA CGM, and FSP. The capital raise is not unexpected, given prior rumours and Eutelsat's financing needs. The higher su

June 20, 2025 June 20, 2025 1 EN

Oscar Haffen Lamm

Oscar Haffen Lamm

Camurus: CAM2029 Ph2/3 in PLD met primary endpoint, follow up Ph3 TBD

Camurus reported topline data from its phase 2/3 POSITANO study (n=71) evaluating CAM2029 in PLD which met the primary endpoint showing stat. sig. relative reduction of the liver volume (htTLV) from baseline to week 53 of 4.3% (p=0.044) vs pbo, with corresponding relative reduction in total liver c

June 18, 2025 June 18, 2025 1 EN

Oscar Haffen Lamm

Oscar Haffen Lamm

Medincell FY24: Uzedy TRx growth momentum; Runway to profitability

Medincell’s FY24 results primarily focused on balance sheet items and a recap of corporate achievements. Importantly, Uzedy’s TRx data continues to show sustained momentum, which we view as a key metric to forecast future growth - we maintain our expectation of accelerating sales into FY25 (FYe: US

June 18, 2025 June 18, 2025 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

NEL: CMD : attractive roadmap in terms of product development and cost reduction | BUY | NOK33(-1%)

Energy transition & Sustainability Green hydrogen finally ready for take-off | HydrogenPro initiation of coverage Buy – Tprice NOK50/share

NEL: Record order for 200 MW of alkaline electrolyser | SELL | NOK10

NEL: Top-line below expectations, challenged by supply chain disruptions | SELL | NOK10

Eutelsat: EUR1.35bn raise and step towards becoming a strategic French asset

Camurus: CAM2029 Ph2/3 in PLD met primary endpoint, follow up Ph3 TBD

Medincell FY24: Uzedy TRx growth momentum; Runway to profitability

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe